Literature DB >> 15243791

Fever in neutropenia in children and adolescents: evolution over time of main characteristics in a single center, 1993-2001.

Roland A Ammann1, Christoph Aebi, Andreas Hirt, Annette Ridolfi Lüthy.   

Abstract

GOALS OF WORK: To assess the evolution over time of main characteristics of episodes of fever in severe chemotherapy-induced neutropenia (FN) in children and adolescents with cancer treated for FN following nonmyeloablative chemotherapy, to compare the results with the experiences of other centers, and to assess the impact of the changes found on management of FN and on risk prediction rules. PATIENTS AND METHODS: Retrospective cohort study of all children and adolescents up to 18 years presenting with FN in a single pediatric oncology unit between 1993 and 2001. MAIN
RESULTS: In 132 patients, 364 episodes of FN were reported. The relative incidence of FN increased significantly over time in patients with precursor B-cell acute lymphoblastic leukemia (PBC-ALL), reflecting the increased intensity of chemotherapy. At presentation with FN, the proportions of patients (1) with PBC-ALL versus other malignancies, (2) with other malignancies being in complete remission, (3) with a central venous catheter, and (4) with shaking chills all significantly increased over time (overall proportions, 64%, 60%, 50%, and 5%, respectively; p <0.001 for all). In 337 (93%) episodes, ceftriaxone plus amikacin was used as empirical broad spectrum antimicrobial therapy.
CONCLUSIONS: This study demonstrates that some characteristics of FN, though not necessarily its management, change over time, implying regular update of risk prediction rules. In contrast to other centers, the first-line antimicrobial therapy did not need modification because of changing resistance patterns.

Entities:  

Mesh:

Year:  2004        PMID: 15243791     DOI: 10.1007/s00520-004-0660-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  22 in total

1.  Suspected infection in children with cancer.

Authors:  Peter J Shaw
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

2.  Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.

Authors:  R Charnas; A R Lüthi; W Ruch
Journal:  Pediatr Infect Dis J       Date:  1997-04       Impact factor: 2.129

3.  Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer.

Authors:  V M Aquino; L Herrera; E S Sandler; G R Buchanan
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

4.  Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia.

Authors:  E S de Bont; E Vellenga; J C Swaanenburg; V Fidler; P J Visser-van Brummen; W A Kamps
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

5.  Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever.

Authors:  M E Santolaya; A M Alvarez; A Becker; J Cofré; N Enríquez; M O'Ryan; E Payá; J Pilorget; C Salgado; J Tordecilla; M Varas; M Villarroel; T Viviani; M Zubieta
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

6.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia.

Authors:  R J Klaassen; T R Goodman; B Pham; J J Doyle
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

8.  Predicting bacteremia in children with fever and chemotherapy-induced neutropenia.

Authors:  Roland A Ammann; Andreas Hirt; Annette Ridolfi Lüthy; Christoph Aebi
Journal:  Pediatr Infect Dis J       Date:  2004-01       Impact factor: 2.129

9.  The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis.

Authors:  K G Lucas; A E Brown; D Armstrong; D Chapman; G Heller
Journal:  Cancer       Date:  1996-02-15       Impact factor: 6.860

10.  The changing epidemiology of bacteremia in neutropenic children with cancer.

Authors:  V M Aquino; A Pappo; G R Buchanan; I Tkaczewski; M M Mustafa
Journal:  Pediatr Infect Dis J       Date:  1995-02       Impact factor: 2.129

View more
  4 in total

1.  Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma.

Authors:  Denise Willmer; Stefan K Zöllner; Frieder Schaumburg; Heribert Jürgens; Thomas Lehrnbecher; Andreas H Groll
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

2.  Pediatric patients at risk for fever in chemotherapy-induced neutropenia in Bern, Switzerland, 1993-2012.

Authors:  Annina N von Allmen; Maxime G Zermatten; Kurt Leibundgut; Philipp Agyeman; Roland A Ammann
Journal:  Sci Data       Date:  2018-03-13       Impact factor: 6.444

3.  Episodes of fever in neutropenia in pediatric patients with cancer in Bern, Switzerland, 1993-2012.

Authors:  Maxime G Zermatten; Christa Koenig; Annina von Allmen; Philipp Agyeman; Roland A Ammann
Journal:  Sci Data       Date:  2019-01-15       Impact factor: 6.444

Review 4.  Febrile neutropenia in children with cancer.

Authors:  Stéphane Paulus; Simon Dobson
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.